BDR Pharma to acquire stake in Acme’s oral solid formulations business
Existing investors, including private equity firm PAG, are selling their stakes in Acme's oral solids formulations business in a transaction that is expected to value the business at about $250 million.
Open True Mainstream to compare left, right, and center coverage